Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus
Status unconfirmed · Not applicable
Conditions studied: Barrett Esophagus, Esophageal Cancer
In brief
Esophageal cancer is a deadly disease that is becoming increasingly common in the United States. Barrett's esophagus (BE) is a pre-cancerous state that can develop into esophageal cancer, but is highly treatable. Progression of BE to esophageal cancer is still common due to missed diagnosis of Barrett's esophagus recurrence following treatment. Wide-Area Trans-Epithelial Sampling (WATS-3D) is a new technology that uses brush sampling to examine larger areas of the esophagus as compared to conventional biopsies. Preliminary studies show improved detection of cancerous changes in Barrett's esophagus surveillance. The investigators hope to see if the addition of WATS-3D increases the rate of detection of recurrent BE following treatment, which is of the utmost importance since it would allow for earlier re-treatment of disease and ultimately allow for prevention of progression to esophageal cancer.
Key facts
- Study ID
- NCT05056051
- Run by
- Northwestern University
- People needed
- 200
- Starts
- 2020-10-01
- Expected to finish
- 2025-06-30
- Last updated by the study team
- 2024-04-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- All patients aged 18+ diagnosed with Barrett's esophagus with confirmed histologic dysplasia or intra-mucosal cancer undergoing surveillance after EET
- Patients who have achieved CE-IM on at least one surveillance endoscopy following EET
- All subjects must have given signed, informed consent prior to registration in the study
You may not qualify if…
- All patients who are unable or unwilling to give consent will not be included in the study
- All patients deemed to have refractory BE despite EET
- Patients who are pregnant, vulnerable populations such as prisoners, life expectancy < 1 year based on concurrent comorbidities, coagulopathy with INR > 1.5 that cannot be reversed, thrombocytopenia with platelets < 125,000 that cannot be corrected with blood products, unable to safely undergo elective endoscopy due to current comorbidities, and inability to pass standard endoscope will not be included in the study
Where it is running
- Northwestern Memorial Hospital — Chicago, Illinois, United States (enrolling)
- University of California, LA — Los Angeles, California, United States
- University of Colorado — Aurora, Colorado, United States
- Washington University in St. Louis, Barnes Jewish Hospital — St Louis, Missouri, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.